Evidence map›Paper›PMID 40593375›Full record

ArticleVirchows Archiv : an international journal of pathology2025

Histologic characteristics and predictors of outcome in epithelial-myoepithelial carcinoma (EMC) of salivary gland: a multi-center study of 75 cases.

Bin Xu, Kartik Viswanathan, Michelle Afkhami, Mike Mikula, Dan Lubin, Kelly Magliocca, Dibisha Roy, Ronald Ghossein, Diana Bell, Lisa Rooper and 1 more

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Virchows Archiv : an international journal of pathology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Bin XuDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA.
Kartik ViswanathanDepartment of Pathology and Laboratory Medicine, School of Medicine, Emory University, Atlanta, GA, USA.
Michelle AfkhamiDepartment of Pathology, City of Hope, Duarte, CA, USA.
Mike MikulaDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Dan LubinDepartment of Pathology and Laboratory Medicine, School of Medicine, Emory University, Atlanta, GA, USA.
Kelly MaglioccaDepartment of Pathology and Laboratory Medicine, School of Medicine, Emory University, Atlanta, GA, USA.
Dibisha RoyDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA.
Ronald GhosseinDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA.
Diana BellDepartment of Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
Lisa RooperDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Nora KatabiDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA. katabin@mskcc.org.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
NCI NIH HHS P30CA008748
6 · The paper itself

Abstract

Epithelial-myoepithelial carcinoma (EMC) may occur de novo or ex pleomorphic adenoma (PA). We aimed to investigate the prognostic and clinicopathologic features and the utility of RAS Q61R immunohistochemistry in a multicenter retrospective cohort of 75 EMCs. Seven tumors (9%) were EMC ex PA, whereas 91% (n = 68) were EMC de novo. Compared with EMC de novo, EMC ex PA was associated with a significant higher percentage of hyalinized and myxoid stroma, larger tumor size, frequent perineural invasion (PNI), absence of nuclear enlargement, and lower frequency of pT1 disease. Seven out of 65 patients had adverse events (five local recurrence, two regional recurrences, two distant metastases, and two disease-related death). The 5-year and 10-year disease-specific survival were 100% and 91% respectively, and the 5-year and 10-year disease-free survival (DFS) were 90% and 85% respectively. Adverse pathologic features that were associated with RFS on univariate survival analysis included PNI, atypical mitosis, mitotic count, and tumor size ≥ 4 cm. Among them, PNI and atypical mitosis remained as independent prognostic factors on multivariate survival analysis. The frequency of RAS Q61R immunopositivity was 31% (12/39) in EMC de novo, 0% (0/5) in EMC ex PA, and 0% (0/32) in non-EMC salivary neoplasms. In conclusion, although most of the EMCs are de novo, 9% are EMCs ex PA. PNI, mitotic index, atypical mitosis, and large tumor size predict shortened RFS in EMC. RAS Q61R immunopositivity is highly specific for EMC de novo and is absent in EMC ex PA.

Indexed as

Adenoma, PleomorphicCarcinomaMyoepitheliomaSalivary Gland NeoplasmsAdultAgedAged, 80 and overBiomarkers, TumorDisease-Free SurvivalFemaleHumansImmunohistochemistryMaleMiddle AgedNeoplasm Recurrence, LocalPrognosisBiomarkers, TumorEpithelial-myoepithelial carcinomaPrognosisRASSalivary gland carcinoma

Identifiers

PMID40593375

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.